Shin-Ichi Haginomori

Shin-Ichi Haginomori

Auto-generated profile, based on publicly available information

Shin-Ichi Haginomori

Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City 569-8686, Osaka, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2013 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
MSMinoru Suzuki
Minoru Suzuki
IKIturo Kato
Ituro Kato
TATeruhito Aihara
Teruhito Aihara
JHJunichi Hiratsuka
Junichi Hiratsuka
KYKenichi Yoshimura
Kenichi Yoshimura
AMAkira Maruhashi
Akira Maruhashi
We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records. Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10–12 Gy-eq to the skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range, 0.7–40.8). A total of 87 BNCT procedures were performed. The overall response rate was 58% within 6 months after BNCT. The median survival time was 10.1 months from the time of BNCT. The 1- and 2-year overall survival (OS) rates were 43.1% and 24.2%, respectively. The major acute Grade 3 or 4 toxicities were hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stomatitis (9.7%) and pain (9.7%), all of which were manageable. Three patients died of treatment-related toxicity. Three patients experienced carotid artery hemorrhage, two of whom had coexistent infection of the carotid artery. This study confirmed the feasibility of our dose-estimation method and that controlled trials are warranted.

1 January 1994 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
YOYoshimitsu Ohinata
Yoshimitsu Ohinata
KMKazuo Makimoto
Kazuo Makimoto
MKMichtro Kawakami
Michtro Kawakami
SHShin-Ichi Haginomori
Shin-Ichi Haginomori
MAMichitoshi Araki
Michitoshi Araki
HTHiroaki Takahashi
Hiroaki Takahashi
Blood viscosity and plasma viscosity were measured in 51 patients wth sudden deafness (SD) and 70 controls with normal hearing. Blood viscosity and plasma viscosity in patients with SD at their first medical examination were significantly higher than in the control group. The diference in viscosimetry results between the two groups was greater at higher shear rates. The data obtained in viscosinietry and pure-tone audiometry were analyzed after dividing the patients into a high viscosity group and a normal viscosity group. The correlation between average hearing levcl in pure-tone audiogram and blood viscosity or plasma viscosity was positive. The valucs of the 0, -transport capacity of the blood demonstrated a negative correlation with average hearing level in patients with SD before treatment. During the course of treatment, blood viscosity and plasma viscosity decreased with the improvement of hearing impairment. When the distribution of average hearing level was 40 to 79 dB, a few of the patients with “recovery” or “good improvement” and most of patients with “fair improvement” or “no change” belonged to the low viscosity group. And, most of the patients with flat type hearing impairment and a few patients with high tone type hearing impairment belonged to the high viscosity group. These results suggest that many patients with SD have increased blood viscosity and plasma viscosity, and that this increase may play a significant role in the etiology of SD. There are also some differences in etiologic factors concerning type of hearing impairment and prognosis. In conclusion, the present study points to the importance of measuring blood viscosity and plasma viscosity in patients with SD, since blood and/or plasma viscosity may be involved in its etiology and prognosis.

17 April 1998 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KKKeiichi Kameoka
Keiichi Kameoka
HIHaruhiko Isotani
Haruhiko Isotani
KTKoji Tanaka
Koji Tanaka
KAKanako Azukari
Kanako Azukari
YFYukari Fujimura
Yukari Fujimura
NONakaaki Ohsawa
Nakaaki Ohsawa

1 June 2008 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SHShin-Ichi Haginomori
Shin-Ichi Haginomori
ATAtsuko Takamaki
Atsuko Takamaki
RNRyuzaburo Nonaka
Ryuzaburo Nonaka
HTHiroshi Takenaka
Hiroshi Takenaka
The goals of cholesteatoma surgery are to prevent residual or recurrent cholesteatomas and to restore hearing. A recurrent cholesteatoma arises from a new postoperative retraction pocket with a crust1,2 that requires frequent cleaning or cannot be cleaned sufficiently because of poor ventilation of the middle ear. A residual cholesteatoma develops from matrix that was not removed at tympanoplasty and depends on the surgical maneuvers performed by the otologist.1,2 Residual matrix is frequently observed at the sinus tympani, oval window, middle cranial fossa, and bone dehiscence of the facial canal. Surgeons always attempt to decrease the incidence of residual cholesteatomas, for example, by using a small mirror or endoscope to observe the middle ear.

1 January 2007 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
AKAtsuko Kanazawa
Atsuko Kanazawa
SHShin-Ichi Haginomori
Shin-Ichi Haginomori
ATAtsuko Takamaki
Atsuko Takamaki
RNRyuzaburo Nonaka
Ryuzaburo Nonaka
MAMichitoshi Araki
Michitoshi Araki
HTHiroshi Takenaka
Hiroshi Takenaka
Conclusion. The present study indicates that recovery from Bell's palsy in a diabetic group (DG) is delayed, and the facial movement score remains low in comparison with a nondiabetic group (NDG). More aggressive treatments, such as higher-dose corticosteroid administration and/or facial nerve decompression surgery, might be considered in diabetic patients with severe Bell's palsy. Objectives. The purpose of this study was to reveal prognostic differences for Bell's palsy in the DG and NDG. Patients and methods. The grades of facial palsy in 19 diabetic and 57 nondiabetic patients with Bell's palsy were assessed using the House-Brackmann grading system (HB system). Recovery was defined as grade I. The average of HB system grades and recovery rates were compared in the DG and NDG at the start of the treatment, and 1 month, 3 months, and 6 months after onset. Results. There were no differences in the HB system between the DG and NDG at the start of treatment and at 1 month after onset. However, facial movement in the DG was poorer than that in the NDG at 3 months and 6 months after onset. In terms of the recovery rate, the rate in the DG (52.6%) was much lower than that in the NDG (82.5%) at 6 months after onset.

9 December 2018 in Head & Neck
Verified
Journal Article
Closed access
PDF file
MSManabu Suzuki
Manabu Suzuki
RKRyo Kawata
Ryo Kawata
MHMasaaki Higashino
Masaaki Higashino
SNShuji Nishikawa
Shuji Nishikawa
TTTetsuya Terada
Tetsuya Terada
Yoshinobu HiroseYoshinobu Hirose
Yoshinobu Hirose